Alnylam Pharmaceuticals Inc (ALNY)

Nov 12, 2026

Alnylam Pharmaceuticals (ALNY) stock rose 5.4% on Wednesday, November 11, 2026, while the broader S&P 500 gained 1.3%. This surge occurred despite the company not reporting earnings and followed a significant drop earlier due to management's dissatisfaction with demand growth and lower sales expectations for its TTR drugs. The gain helped Alnylam recover from a year-low, aligning with a wider market rally driven by eased worries about AI profits, though it still faces a substantial year-over-year decline.

Nov 11, 2026

Eli Lilly's stock reached a 52-week high after announcing strong third-quarter growth driven by its GLP-1 agonists Mounjaro and Zepbound. In stark contrast, Alnylam Pharmaceuticals' stock hit a 52-week low on the same day as it reported its third-quarter results. Both companies are heavily reliant on dominant franchises, with Lilly's success attributed to its diabetes and obesity drugs, while Alnylam faced challenges.

Nov 5, 2026

This article identifies three healthcare stocks—Alnylam Pharmaceuticals (ALNY), Madrigal Pharmaceuticals (MDGL), and Corcept Therapeutics (CORT)—that are currently oversold, indicating a potential buying opportunity for investors in Q4. Each company has experienced a recent stock decline, placing their Relative Strength Index (RSI) near or below 30, a key indicator for oversold assets. The article highlights recent company announcements and financial performance, suggesting these stocks may be undervalued.

Nov 2, 2026

Alnylam Pharmaceuticals (ALNY) stock recently dropped significantly after its Q3 2026 earnings report, due to management's concerns about demand growth. Historically, similar drops in Alnylam's stock have led to higher prices a year later less than half the time, with mixed results. The company is still growing drug sales and generating cash, but its short-term outlook is impacted by slower patient starts and potential hospital ordering caution due to the 340B drug discount program.